Change of IL-4 and IL-6 levels in blood plasma of patients transplanted with allogeneic hematopoietic stem cells determined by protein chip and its relationship with aGVHD.
- Author:
Yu JING
1
;
Li YU
;
Guang-Hong GUO
;
Ya-Ping TIAN
Author Information
1. Department of Hematology, The General Hospital of PLA, Beijing 100853, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Biomarkers;
blood;
Female;
Graft vs Host Disease;
blood;
Hematopoietic Stem Cell Transplantation;
adverse effects;
Humans;
Interleukin-4;
blood;
Interleukin-6;
blood;
Leukemia;
blood;
therapy;
Male;
Middle Aged;
Protein Array Analysis;
Transplantation, Homologous;
Young Adult
- From:
Journal of Experimental Hematology
2008;16(2):360-363
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to explore the relationship between changes of IL-4, IL-6 levels in blood plasma of patients receiving allo-HSCT and aGVHD through dynamical detection. The IL-4 and IL-6 levels in peripheral blood were detected by protein chip and were observed for 10 weeks. The results indicated that the IL-4 level increased rapidly in 1 week after transplantation in aGVHD group and was higher than that of non aGVHD group (p<0.05), while at 7th week after transplantation IL-4 level increased rapidly in non-GVHD group and was higher than that of aGVHD group (p<0.01). There was a significant difference of IL-6 level between these two groups before transplantation. IL-6 level reached peak at 1st week after transplantation in aGVHD group and was higher than that of non-aGVHD group (p<0.01), while IL-6 level was significantly higher in non-aGVHD group than that of aGVHD group at 4th week after transplantation (p<0.01) and at 5th week after transplantation (p<0.05). It is concluded that the levels of IL-4 and IL-6 had been increased rapidly after hematopoietic stem cell transplantation, indicating that aGVHD will occur. The high level of IL-6 before transplantation may be the risk factor of aGVHD occurrence after transplantation. aGVHD may occur later if the blood plasma IL-4 level rises in patients without aGVHD. Therefore, dynamically monitoring IL-4 and IL-6 levels contributes to predict the occurrence of aGVHD.
